Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

Emanuelle M. Rizk, Robyn D. Gartrell, Luke W. Barker, Camden L. Esancy, Grace G. Finkel, Darius D. Bordbar, Yvonne M. Saenger

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

Original languageEnglish (US)
Pages (from-to)291-299
Number of pages9
JournalHematology/Oncology Clinics of North America
Issue number2
StatePublished - Apr 2019
Externally publishedYes


  • Checkpoint inhibition
  • Immunohistochemistry
  • Immunotherapy
  • Predictive and prognostic biomarkers

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy'. Together they form a unique fingerprint.

Cite this